A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

Trial Profile

A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2018

At a glance

  • Drugs Solriamfetol (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Jazz Pharmaceuticals Inc
  • Most Recent Events

    • 27 Aug 2018 Status changed from active, no longer recruiting to completed.
    • 29 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 04 Jun 2018 Planned End Date changed from 1 Apr 2018 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top